reports
- Oscar Haffen Lamm
Additional positive data in adolescents to support Ixchiq label extens...
Valneva reported additional positive phase 3 data for its single-shot Ixchiq vaccine (CHIKV) in adolescents. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of the study VLA1553-321 evaluated the safety and immunogenicity six months (Day 180) after vaccination
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents f...
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine Results Intended to Support Filing for Potential Label Extension for Use in Adolescents Saint-Herblain (France), May 13, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months (D...
- Olfa Taamallah
- Yan Derocles
VLS VALNEVA SE
ELG ELMOS SEMICONDUCTOR SE
NOEJ NORMA GROUP SE
ELIS ELIS SA
SHA SCHAEFFLER AG
KRN KRONES AG
PSPN PSP SWISS PROPERTY AG
SIGHT GENSIGHT BIOLOGICS SA
BEZ BERENTZEN GRUPPE
ASS APPLUS SERVICES S.A.
COFA COFACE SA
JUN3 JUNGHEINRICH AG PREF
IDR INDRA SISTEMAS S.A. CLASS A
TMV TEAMVIEWER AG
HAG HENSOLDT AG
- Olfa Taamallah
- Yan Derocles
VLS VALNEVA SE
ELG ELMOS SEMICONDUCTOR SE
NOEJ NORMA GROUP SE
ELIS ELIS SA
SHA SCHAEFFLER AG
KRN KRONES AG
PSPN PSP SWISS PROPERTY AG
SIGHT GENSIGHT BIOLOGICS SA
BEZ BERENTZEN GRUPPE
ASS APPLUS SERVICES S.A.
COFA COFACE SA
JUN3 JUNGHEINRICH AG PREF
IDR INDRA SISTEMAS S.A. CLASS A
TMV TEAMVIEWER AG
HAG HENSOLDT AG
- Damien Choplain
- Martial Descoutures
Valneva : Disappointing Q1 due to supply constraints – guidance confir...
>Top and bottom line below expectations - Q1 revenues came in 2% lower at € 32.8m (-24% vs cs) with product sales stable at € 32.1m (-21% vs cs). This disappointing performance can mainly be attributed to supply issue for Ixiaro which showed a decline of 5% (-34% vs cs). Dukoral saw sales grow by 10% to € 11.3m (+18% vs cs) underpinned by a recovery in the traveller market. As expected, third-party distribution (-9%, -33% vs Cs) suffered from supply constraints for t...
- Oscar Haffen Lamm
Valneva: reports Q1, full year guidance reiterated
Valneva reported its Q1 2024 results where revenues came in at EUR 32.8m (vs css EUR 43.1m), including product sales of EUR 32.1m, driven by Ixiaro (EUR 16.6m, -4.8%), Dukoral (EUR 11.3m, +10.3%), and third party products (EUR 4.1m, -8.9%). The decrease in Ixiaro sales is mainly attributed by the s
- Damien Choplain
- Martial Descoutures
Valneva : T1 décevant lié à des contraintes d’approvisionnement – Guid...
>En dessous de attentes en topline et bottom line - Les revenus T1 sont en baisse de 2% à 32.8 M€ (-24% vs css) avec des ventes de produits stables à 32.1 M€ (-21% vs css). Cette performance décevante s’explique principalement par des problèmes d'approvisionnement sur Ixiaro qui ressort en baisse de 5% (-34% vs css). Dukoral affiche une croissance de 10% à 11.3 M€ (+18% vs css) soutenue par la reprise du marché du voyageur. Comme prévu, la distribution pour tiers (-9%...
- Christophe Chaput
Beneteau : Strong drop in Q1 sales, as expected, due to inventory redu...
>Q1 sales down 26.9% to € 348.7m (ODDO BHF: € 384.4m est.) - The Bénéteau group reported Q1 sales down 27.1% to € 348.7m, a more pronounced decline than we expected (our estimate € 384.4m; difference -9%). By division, this slowdown in sales in Q1 is attributable to: 1/ A strong fall in boat sales of 39% to € 228.7m (ODDO BHF: € 281.3m) due to a high base of comparison (Q1 2023 boat sales: +57%) as well as inventory drawdowns at distributors. By segment, we note...
- Christophe Chaput
Bénéteau : CA T1 en forte baisse, comme attendu, sous l’effet des dést...
>CA T1 en baisse de 26.9% à 348.7 M€ (ODDO BHF : 384.4 M€e) - Le groupe Bénéteau publie un CA T1 en recul de 27.1% à 348.7 M€ soit un déclin plus prononcé que nous ne l’estimions (384.4 M€ estimé ; différence -9%). Par pôle d’activité, ce ralentissement des ventes au T1 s’explique par : 1/ Une forte baisse du CA Bateaux de 39% à 228.7 M€ (ODDO BHF : 281.3 M€) en raison d’un effet de base élevé (CA Bateaux T1 2023 : +57%) ainsi que du déstockage des distributeurs...
Valneva Reports First Quarter 2024 Financial Results and Provides Cor...
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year guidance Cash position of €176.6 million, including €95 million from sale of Priority Review Voucher (PRV)1. Significantly extended cash runway with recent update of debt financing agreement2Substantially lower cash burn expected in 2024 as Valneva expects to complete...
Valneva publie ses résultats financiers du premier trimestre 2024 et f...
Valneva publie ses résultats financiers du premier trimestre 2024 et fait un point sur ses activités Valneva publie ses résultats financiers du premier trimestre 2024 et fait un point sur ses activités Principaux éléments financiers du premier trimestre Chiffre d’affaires total de 32,8 millions d’euros dont 32,1 millions d’euros de ventes de produits, en ligne avec les prévisions pour l'exercice 2024Position de trésorerie de 176,6 millions d’euros dont 95 millions d’euros provenant de la vente du bon de revue prioritaire (PRV)1. Extension significative de la visibilité financière ...
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE VALNEVA Declaration of shares and voting rights April 30, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: May 6, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change D...
BioSenic S.A. : Information on the total number of voting rights and ...
BioSenic S.A. : Information on the total number of voting rights and shares PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, April 30, 2024, 7.00 am CEST – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of major shareholdings in issuers...
BioSenic publie sur son site web le plan de restructuration soumis au ...
BioSenic publie sur son site web le plan de restructuration soumis au tribunal des entreprises de Nivelles COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE Mont-Saint-Guibert, Belgique, le 26 avril 2024 à 17h30 CEST – (Euronext Bruxelles et Paris: BIOS), la société en phase clinique spécialisée dans les maladies auto-immunes et inflammatoires graves, dans le cadre du plan de restructuration global annoncé le 11 avril 2024, annonce aujourd'hui la publication sur son site internet de la documentation suivante : Le plan de restructuration couvrant les années 2024-2030 soumis au Tribunal...
BioSenic publishes on its website the restructuring plan submitted to ...
BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 26 April 2024, 17:30 CET – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases, as part of the global restructuring plan announced on 11 April 2024, today announces the publication on its website of the following documentation : The restructuring plan covering the years 2024-2030 submitted to the Enterprise Court of Nivelles – accessible via th...
BioSenic postpones its annual general meeting of the shareholders and ...
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023 PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going...
BioSenic reporte son assemblée générale annuelle des actionnaires et f...
BioSenic reporte son assemblée générale annuelle des actionnaires et fournit des chiffres financiers temporaires non-audités pour 2023 COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE Compte tenu du plan de restructuration annoncé le 11 avril 2024, BioSenic a décidé de reporter la publication de son rapport annuel 2023 ainsi que son assemblée générale annuelle des actionnaires, afin que le Tribunal de l'entreprise de Nivelles puisse prendre une décision avant l'accomplissement des formalités annuelles. La société estime que ce report est préférable pour s'assurer que les états financiers pe...
BioSenic S.A. : Transparency notifications received from François Rie...
BioSenic S.A. : Transparency notifications received from François Rieger PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, April 18, 2024, 7am CET – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received transparency notifications from François Rieger. Details of the notifications can be found below and the full versions of the transparency declarations are available ...
BioSenic S.A. : Notifications de transparence reçues de la part de Fr...
BioSenic S.A. : Notifications de transparence reçues de la part de François Rieger COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes Mont-Saint-Guibert, Belgique, le 18 avril 2024 à 7h00 CET – (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto-immunes et inflammatoires graves et dans la thérapie cellulaire, annonce aujourd’hui la réception de notifications de transparence de François Rieger. Les détails des notifications peuvent être trou...
BioSenic provides further information on its restructuring plan
BioSenic provides further information on its restructuring plan PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 12 April 2024, 12:00 CET – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, as part of the global restructuring plan announced on 11 April 2024, provides information on (i) the Company's current debt position and the potential impact of the plan on this position and (ii) links to the Company's website to consult the conversion terms and conditions offered to h...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.